Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma

Anticancer Research

Volumn 33, Issue 3, 2013, Pages 755-762

  Mueller, Sabine ^a,b   Bhargava, Samhita ^c   Molinaro, Annette M ^a,b   Yang, Xiaodong ^a   Kolkowitz, Ilan ^a   Olow, Aleksandra ^a   Wehmeijer, Noor ^d   Orbach, Sharon ^a   Chen, Justin ^a   Matthay, Katherine K ^a   Haas Kogan, Daphne A ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MOUNT SINAI MEDICAL CENTER   (United States)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

DNA repair; Metastatic neuroblastoma; MK 4827; PARP inhibition; Radiation

Indexed keywords

CASPASE 3; HISTONE H2AX; HISTONE H2AX GAMMA; KI 67 ANTIGEN; NIRAPARIB; POLY(ADENOSINE DIPHOSPHATE RIBOSE); UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER RADIOTHERAPY; CELL SURVIVAL; CLONOGENESIS; CONTROLLED STUDY; CYTOTOXICITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; METASTASIS; MOUSE; NEUROBLASTOMA; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIZATION;

ANIMALS; CASPASE 3; CELL LINE, TUMOR; CHEMORADIOTHERAPY; ENZYME INHIBITORS; FEMALE; HISTONES; HUMANS; INDAZOLES; MICE; NEOPLASM METASTASIS; NEUROBLASTOMA; PIPERIDINES; POLY(ADP-RIBOSE) POLYMERASES; RADIATION-SENSITIZING AGENTS;

EID: 84875890173     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. London WB, Castel V, Monclair T, Ambros PF, Pearson AD, Cohn SL, Berthold F, Nakagawara A, Ladenstein RL, Iehara T and Matthay KK: Clinical and biologic features predictive of survival after relapse of neuroblastoma: a report from the International Neuroblastoma Risk Group project. J Clin Oncol 29: 3286-3292, 2011.
2. Kumar R, Horikoshi N, Singh M, Gupta A, Misra HS, Albuquerque K, Hunt CR and Pandita TK: Chromatin modifications and the DNA damage response to ionizing radiation. Front Oncol 2: 214, 2012.
3. Krishnakumar R and Kraus WL: The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39: 8-24, 2010.
4. Calabrese CR, Almassy R, Barton S, Batey MA, Calvert AH, Canan-Koch S, Durkacz BW, Hostomsky Z, Kumpf RA, Kyle S, Li J, Maegley K, Newell DR, Notarianni E, Stratford IJ, Skalitzky D, Thomas HD, Wang LZ, Webber SE, Williams KJ and Curtin NJ: Anticancer chemosensitization and radiosensitization by the novel poly(ADP-ribose) polymerase-1 inhibitor AG14361. J Natl Cancer Inst 96: 56-67, 2004.
5. Veuger SJ, Curtin NJ, Richardson CJ, Smith GC and Durkacz BW: Radiosensitization and DNA repair inhibition by the combined use of novel inhibitors of DNA-dependent protein kinase and poly(ADP-ribose) polymerase-1. Cancer Res 63: 6008-6015, 2003.
6. Shiobara M, Miyazaki M, Ito H, Togawa A, Nakajima N, Nomura F, Morinaga N and Noda M: Enhanced polyadenosine diphosphate-ribosylation in cirrhotic liver and carcinoma tissues in patients with hepatocellular carcinoma. J Gastroenterol Hepatol 16: 338-344, 2001.
7. Mueller S, Yang X, Sottero TL, Gragg A, Prasad G, Polley MY, Weiss WA, Matthay KK, Davidoff AM, DuBois SG and Haas- Kogan DA: Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Lett 306: 223-229, 2011.
8. Franken NA, Rodermond HM, Stap J, Haveman J and van Bree C: Clonogenic assay of cells in vitro. Nat Protoc 1: 2315-2319, 2006.
9. Dickson PV, Hamner B, Ng CY, Hall MM, Zhou J, Hargrove PW, McCarville MB and Davidoff AM: In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma. J Pediatr Surg 42: 1172-1179, 2007.
10. Dean E, Middleton MR, Pwint T, Swaisland H, Carmichael J, Goodege-Kunwar P and Ranson M: Phase I study to assess the safety and tolerability of olaparib in combination with bevacizumab in patients with advanced solid tumours. Br J Cancer 106(3): 468-474, 2012.
11. Samol J, Ranson M, Scott E, Macpherson E, Carmichael J, Thomas A and Cassidy J: Safety and tolerability of the poly(ADP-ribose) polymerase (PARP) inhibitor, olaparib (AZD2281) in combination with topotecan for the treatment of patients with advanced solid tumors: A phase I study. Invest New Drugs 30(4): 1493-1500, 2012.
12. Daniel RA, Rozanska AL, Thomas HD, Mulligan EA, Drew Y, Castelbuono DJ, Hostomsky Z, Plummer ER, Boddy AV, Tweddle DA, Curtin NJ and Clifford SC: Inhibition of poly(ADP-ribose) polymerase-1 enhances temozolomide and topotecan activity against childhood neuroblastoma. Clin Cancer Res 15: 1241-1249, 2009.
13. Efimova EV, Mauceri HJ, Golden DW, Labay E, Bindokas VP, Darga TE, Chakraborty C, Barreto-Andrade JC, Crawley C, Sutton HG, Kron SJ and Weichselbaum RR: Poly(ADP-ribose) polymerase inhibitor induces accelerated senescence in irradiated breast cancer cells and tumors. Cancer Res 70: 6277-6282, 2011.
14. Senra JM, Telfer BA, Cherry KE, McCrudden CM, Hirst DG, O'Connor MJ, Wedge SR and Stratford IJ: Inhibition of PARP-1 by Olaparib (AZD2281) increases the radiosensitivity of a lung tumor xenograft. Mol Cancer Ther 10: 1949-1958, 2011.
15. Schreiber V, Ame JC, Dolle P, Schultz I, Rinaldi B, Fraulob V, Menissier-de Murcia J and de Murcia G: Poly(ADP-ribose) polymerase-2 (PARP-2) is required for efficient base excision DNA repair in association with PARP-1 and XRCC1. J Biol Chem 277: 23028-23036, 2002.
16. Mortusewicz O, Ame JC, Schreiber V and Leonhardt H: Feedback-regulated poly(ADP-ribosyl)ation by PARP-1 is required for rapid response to DNA damage in living cells. Nucleic Acids Res 35: 7665-7675, 2007.
17. Mitchell J, Smith GC and Curtin NJ: Poly(ADP-Ribose) polymerase-1 and DNA-dependent protein kinase have equivalent roles in double-strand break repair following ionizing radiation. Int J Radiat Oncol Biol Phys 75: 1520-1527, 2009.
18. Hegan DC, Lu Y, Stachelek GC, Crosby ME, Bindra RS and Glazer PM: Inhibition of poly(ADP-ribose) polymerase downregulates BRCA1 and RAD51 in a pathway mediated by E2F4 and p130. Proc Natl Acad Sci USA 107: 2201-2206, 2010.